We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





LumiraDx Demonstrates Fast, High Performance, Portable POC Diagnostic Solution

By LabMedica International staff writers
Posted on 24 May 2023

LumiraDx (London, UK) is presenting its innovative diagnostic solutions at this year's WorldLab-EuroMedLab in Rome, Italy, 21-25 May, including its LumiraDx Platform which is designed to perform multiple tests on one single instrument wherever needed. More...

The LumiraDx Platform is similar to a portable laboratory, compact yet capable of delivering lab-grade results in a variety of care settings, thereby bringing clinical decision-making closer to the patient. This rapid, high-performing, portable point-of-care (POC) diagnostic solution employs active microfluidic technology, providing results for a range of analytes, including NT-proBNP, HbA1c, and CRP, within minutes. The single, portable instrument offers a simple and uniform workflow for all tests and is user-friendly - all that's needed is to follow the on-screen video instructions for high-sensitivity results in minutes.

The LumiraDx Platform serves as a cost-effective replacement for multiple POC systems. Its compact, lightweight design, combined with actively controlled microfluidic test strips and secure connectivity, yields lab-grade results in a matter of minutes. Both the device and test strip employ several analytical electronic quality control measures to ensure the test's integrity and validity, with automated functionality checks and test strip performance controls being conducted throughout the test's operational stages. Regardless of whether healthcare professionals are using direct fingerstick or swab methods, the LumiraDx Platform's 'easy to use' test workflow employs 'easy to retrieve' small sampling directly at the patient's side.

With a pipeline of over 30 assays, LumiraDx's POCT menu is primarily focused on some of the most commonly diagnosed or managed conditions, including coagulation disorders, infectious disease, cardiovascular conditions, and diabetes. By integrating multiple technologies and sample types into one device, the LumiraDx Platform facilitates the continued expansion of a comprehensive test menu for conditions diagnosed and managed in community-based healthcare settings.

Related Links:
LumiraDx 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.